Dr. William Moran

"This is an experimental treatment that is reserved for patients who have had more traditional therapies that have failed," said William Moran, M.D., head and neck oncologist at Lutheran General Hospital.It will target people who have had a recurrence of cancer after a primary treatment and who are not responding to follow-up chemotherapy.Approximately one-third of head and neck cancers recur.
...
"Injecting directly into the tumor provides more drug to the site where you want the anti-tumor activity to occur," said Dr. Moran.The therapy will take place in conjunction with chemotherapy.Patients will undergo the injections five days each month for approximately 2 to 6 months.

The objective of this study is to determine whether ONYX-015 can establish improvements in lasting reduction in the size of the treated tumor and increase clinical benefit.This open label, single arm study of ONYX-015 plus intravenous 5-fluorouracil and cisplatin will involve 120 patients.